Skip to main content
. 2020 Mar 24;25(4):932–940. doi: 10.1007/s11605-020-04570-1

Table 4.

Factors associated with mortality

Univariable Multivariable
OR 95% CI p value OR 95% CI p value
Frailty
No frailty Ref Ref
Low frailty 7.14 3.01–16.9 < 0.001 1.44 0.51–4.10 0.494
Intermediate frailty 34.5 14.6–81.9 < 0.001 4.69 1.37–16.0 0.014
High frailty 133.1 51.4–345.1 < 0.001 12.2 2.67–55.5 0.001
Age ≥ 65 years 5.20 3.40–7.96 < 0.001 2.24 0.62–8.07 0.217
Male (vs female) 1.59 1.07–2.37 0.020 0.77 0.26–2.33 0.647
BMI ≥ 30 0.70 0.46–1.06 0.091
White (vs others) 1.06 0.71–1.56 0.790
ASA ≥ 3, n (%) 29.4 11.9–72.4 < 0.001 6.04 0.99–36.89 0.052
Albumin ≤ 3.5 g/dl, n (%) 7.15 4.09–12.51 < 0.001 1.43 0.38–5.38 0.594
Total bilirubin ≥ 1.2 mg/dl, n (%) 3.88 2.58–5.85 < 0.001 1.73 0.57–5.22 0.330
SGOT ≥ 40 U/L 2.81 1.87–4.25 < 0.001 1.98 0.65–6.01 0.228
Creatinine ≥ 1.2, n (%) 5.46 3.65–8.17 < 0.001 1.26 0.38–4.19 0.712
Platelet ≤ 150, n (%) 4.03 2.62–6.22 < 0.001 1.03 0.27–3.88 0.966
Hematocrit ≤ 35, n (%) 5.30 3.47–8.10 < 0.001 1.44 0.38–5.50 0.591
White blood cell ≥ 11 1.71 1.15–2.55 0.008 1.99 0.68–5.81 0.209

No frailty = mFI 0, Low frailty = mFI 1–2, Intermediate frailty = mFI 3–4, High frailty = mFI ≥ 5

BMI body mass index, ASA American Society of Anesthesiologists, SGOT, serum glutamic-oxaloacetic transaminase; italic font represents statistically significant associations